oral glp 1 agonist brand name 5 GLP-1 trends to expect in 2026: Expanded uses, options, and more How GLP-1 medications are transforming

This was likely driven by the desire to avoid a potential messy lawsuit from Novo and increased federal scrutiny of its compounded GLP-1 business

doi: 10.1111/dom.15624 [DOI] [PubMed] [Google Scholar] 142.Maselli DB, Camilleri M

10.1016/j.neuropharm.2017.08.022 [DOI] [PubMed] [Google Scholar] 81.Huang J, Liu Y, Cheng L, Li J, Zhang T, Zhao G, et al

OConnor, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

117 Additionally, to improve patient compliance, it is crucial to extend the drugs half-life